{"id":49,"date":"2020-06-18T05:42:12","date_gmt":"2020-06-18T02:42:12","guid":{"rendered":"https:\/\/sites.uef.fi\/alzheimermarkkeritutkimukset\/?page_id=49"},"modified":"2026-04-02T10:40:13","modified_gmt":"2026-04-02T07:40:13","slug":"framsida","status":"publish","type":"page","link":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/framsida\/?lang=sv","title":{"rendered":"Biomark\u00f6rer f\u00f6r Alzheimers sjukdom"},"content":{"rendered":"\n<h1 class=\"wp-block-heading\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-85 size-medium\" src=\"https:\/\/sites.uef.fi\/alzheimermarkkeritutkimukset\/wp-content\/uploads\/sites\/112\/2020\/11\/ADBIOMARKKERI-Logo-right-600-levea-300x92.jpg\" alt=\"Logo av Biomarker laboratorium\" width=\"300\" height=\"92\" srcset=\"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/wp-content\/uploads\/sites\/112\/2020\/11\/ADBIOMARKKERI-Logo-right-600-levea-300x92.jpg 300w, https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/wp-content\/uploads\/sites\/112\/2020\/11\/ADBIOMARKKERI-Logo-right-600-levea.jpg 600w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/h1>\n\n\n\n<h1 class=\"wp-block-heading\">Hj\u00e4rnbiomark\u00f6rer<\/h1>\n\n\n\n<p> <br><\/p>\n\n\n\n<p>M\u00f6jligheterna till v\u00e5rd av Alzheimers sjukdom \u00f6kar hela tiden, och fler och fler unders\u00f6kningar tyder p\u00e5 att man uppn\u00e5r den st\u00f6rsta och mest l\u00e5ngvariga nyttan n\u00e4r v\u00e5rden kan p\u00e5b\u00f6rjas s\u00e5 tidigt som m\u00f6jligt. En tidig diagnostik av sjukdomen \u00e4r utmanande. En diagnostisering som grundar sig p\u00e5 en klinisk symptombild f\u00f6ruts\u00e4tter oftast en tillr\u00e4ckligt l\u00e5ngvarig uppf\u00f6ljning f\u00f6r att fastst\u00e4lla progressionen.<\/p>\n\n\n\n<p>I hj\u00e4rnforskningsinstitutet vid \u00d6stra Finlands universitetet (It\u00e4-Suomen yliopisto \/ University of Eastern Finland) g\u00f6r vi analyser av Alzheimermark\u00f6rer amyloid-beta 42, Tau och pTau181 i ryggm\u00e4rgsv\u00e4tskan och av pTau181 och pTau217 i plasma. F\u00f6rdelen med dessa analyser \u00e4r att man kan fastst\u00e4lla en framskridande demenssjukdom, speciellt hos patienter med lindriga symptom.<br>  <br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Plasma pTau217<\/h2>\n\n\n\n<p>Plasmatestet pTau217 rekommenderas inte f\u00f6r symtomfria personer eller f\u00f6r personer under 50 \u00e5r. Testet anv\u00e4nds initialt tillsammans med nuvarande diagnostiska metoder. <\/p>\n\n\n\n<p><strong><a href=\"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/wp-content\/uploads\/sites\/112\/2025\/02\/pTau217-Begaran-om-undersokning-230125.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Remissen f\u00f6r pTau217<\/a><\/strong><\/p>\n\n\n\n<p>  <br>  <br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Plasma pTau181<\/h2>\n\n\n\n<p>Plasma pTau181-testning st\u00f6djer kliniskt beslutsfattande, s\u00e4rskilt vid tidig utv\u00e4rdering av minnessymtom och vid v\u00e4gledning av fortsatt diagnostisk utredning. M\u00e4tning av den fosforylerade tauproteinformen pTau181 i plasma kan anv\u00e4ndas hos personer \u00f6ver 55 \u00e5r som uppvisar tecken p\u00e5 kognitiv neds\u00e4ttning. Plasma pTau181-testning har ett utm\u00e4rkt negativt prediktivt v\u00e4rde: ett negativt resultat tyder starkt p\u00e5 att Alzheimers sjukdom sannolikt inte \u00e4r den bakomliggande orsaken till symtomen. Information av plasma pTau181 uppdateras h\u00e4r inom den n\u00e4rmaste tiden.<br><\/p>\n\n\n\n<p>  <br>  <br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Plasma neurofilament<\/h2>\n\n\n\n<p>Information om neurofilament, en mark\u00f6r f\u00f6r nervcellsskada, finns p\u00e5 sidan <a href=\"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/neurofilament\/?lang=sv\">Plasma neurofilament<\/a>.<\/p>\n\n\n\n<div class=\"links-block\">\n\n    \n    <ul class=\"link-list\">\n        \n            \n            <li class=\"link-list-item\">\n                <a href=\"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/neurofilament\/?lang=sv\" class=\"link-reset link hover-scale-down\">\n                    <svg\n        width=\"43\" height=\"25\"\n        viewBox=\"0 0 43 25\"\n        xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n    <path\n        d=\"M30.027 0 43 12.5 30.027 25 27 22.083 34.351 15H0v-5h34.351L27 2.917z\"\n        fill=\"currentColor\"\n        fill-rule=\"evenodd\"\/>\n<\/svg>                    <div>Plasma neurofilament<\/div>\n                <\/a>\n                <div class=\"link-info\">\n                                    <\/div>\n            <\/li>\n\n                <\/ul>\n<\/div>\n\n\n<p><br> <br><\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\">Li-BAm42, Li-Tau och Li-FosTau<\/h2>\n\n\n\n<p>Li-BAm42, Li-Tau och Li-FosTau \u00e4r ackrediterade tester. Laboratoriet \u00e4r ackrediterat testningslaboratorium T320, ackrediteringskrav SFS-EN ISO 15189:2022. P\u00e5 den <a href=\"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/wp-content\/uploads\/sites\/112\/2023\/11\/Begaran-om-undersokning-301123.pdf\">bifogade remissblanketten <\/a>st\u00e5r provm\u00e4ngderna f\u00f6r varje test eller testkombination samt uppgifter om behandling och avs\u00e4ndning av proverna.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Kostnader 1.6.2025 \u21d2<\/h2>\n\n\n\n<p>En analys av ett enskilt protein kostar 185 \u20ac<br>En kombination av tv\u00e5 proteiner kostar 290 \u20ac<br>En samtidig analys av alla tre kostar 388 \u20ac<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Remissblanketten <\/h2>\n\n\n\n<p>Remissblanketten fr\u00e5n och med 13.2.2023: <a href=\"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/wp-content\/uploads\/sites\/112\/2023\/11\/Begaran-om-undersokning-301123.pdf\">h\u00e4r<\/a> <br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Provr\u00f6r <\/h2>\n\n\n\n<p>Provr\u00f6r och leveransinstruktioner f\u00f6r biomark\u00f6rerna f\u00f6r Alzheimers sjukdom (Li-FosTau, Li-Tau, Li-BAm42) \u00e4ndrades fr\u00e5n och med 1.4.2022. Anledningen till f\u00f6r\u00e4ndringen var uppdateringen av Roche Elecsys ECLIA m\u00e4tmetoden och nya preanalytiska rekommendationer.<\/p>\n\n\n\n<figure class=\"wp-block-image alignright\"><img loading=\"lazy\" decoding=\"async\" width=\"261\" height=\"297\" src=\"https:\/\/sites.uef.fi\/alzheimermarkkeritutkimukset\/wp-content\/uploads\/sites\/112\/2022\/03\/Sarstedt-valepohjaputki-2022.png\" alt=\"\" class=\"wp-image-1036\" \/><\/figure>\n\n\n\n<p><strong>Sarstedt CSF false bottom -r\u00f6r 2.5 ml (75 \u00d7 13 mm), polypropylen, REF 63.614.625. <\/strong><\/p>\n\n\n\n<p><strong>Lumbalpunktion 2.5 ml tas direkt i r\u00f6ret <\/strong><strong><u>till markeringslinjen.<\/u><\/strong><\/p>\n\n\n\n<p>2.5 ml prov kr\u00e4vs oavsett om ni beg\u00e4r analysen av en sp\u00e5rsubstans eller en kombination av flera.<\/p>\n\n\n\n<p><strong>Om provet skickas i ett fel r\u00f6r eller volymen \u00e4r mindre \u00e4n 2.0 ml, m\u00e4ts endast Tau och FosTau.<\/strong> Anledningen till detta \u00e4r att r\u00f6rstorlek och provvolym p\u00e5verkar BAm42-resultaten.<\/p>\n\n\n\n<p>Prover beh\u00f6ver inte centrifugeras och f\u00e5r inte h\u00e4lls \u00f6ver i ett nytt r\u00f6r. Provet f\u00f6rvaras i kylsk\u00e5p och skickas vid rumstemperatur inom 24 timmar av provtagning. Vid l\u00e4ngre f\u00f6rvaringstider f\u00f6rvaras och skickas provet vid +4\u00b0C (max 5 dagar) eller fryst minst -20\u00b0C (max 6 m\u00e5nader).<\/p>\n\n\n\n<p>F\u00f6r\u00e4ndringen av provr\u00f6r inverkar inte p\u00e5 Li-FosTau, Li-Tau eller Li-BAm42 gr\u00e4nsv\u00e4rdena.<br><\/p>\n\n\n\n<p><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Referensv\u00e4rden <\/h2>\n\n\n\n<p>Referensv\u00e4rden fr\u00e5n och med 21.11.2023:<\/p>\n\n\n\n<p><strong>4809 Li-FosTau:<\/strong> Normalt under 21 pg\/ml, gr\u00e4nsv\u00e4rden 21\u201326 pg\/ml, patologiskt \u00f6ver 26 pg\/ml<\/p>\n\n\n\n<p><strong>4810 Li-Tau:<\/strong> Normalt under 230 pg\/ml, gr\u00e4nsv\u00e4rden 230\u2013275 pg\/ml, patologiskt \u00f6ver 275 pg\/ml<\/p>\n\n\n\n<p><strong>4811 Li-BAm42:<\/strong> Normalt \u00f6ver 845 pg\/ml, gr\u00e4nsv\u00e4rden 715\u2013845 pg\/ml, patologiskt under 715 pg\/ml<br><\/p>\n\n\n\n<p>  <br>  <br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Ytterligare information:<\/h2>\n\n\n\n<p>Eino Solje, MD<br>University of Eastern Finland<br>Institute of Clinical Medicine &#8211; Neurology<br>P.O. Box 1627<br>FI-70211 Kuopio, Finland<br>eino.solje(at)uef.fi<\/p>\n\n\n\n<p><br><br><\/p>\n\n\n\n<p>Uppdaterat 2.4.2026<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hj\u00e4rnbiomark\u00f6rer M\u00f6jligheterna till v\u00e5rd av Alzheimers sjukdom \u00f6kar hela tiden, och fler och fler unders\u00f6kningar tyder p\u00e5 att man uppn\u00e5r den st\u00f6rsta och mest l\u00e5ngvariga nyttan n\u00e4r v\u00e5rden kan p\u00e5b\u00f6rjas s\u00e5 tidigt som m\u00f6jligt. En tidig diagnostik av sjukdomen \u00e4r utmanande. En diagnostisering som grundar sig p\u00e5 en klinisk symptombild f\u00f6ruts\u00e4tter oftast en tillr\u00e4ckligt l\u00e5ngvarig [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-49","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biomark\u00f6rer f\u00f6r Alzheimers sjukdom - Aivobiomarkkeritutkimukset<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/?lang=sv\" \/>\n<meta property=\"og:locale\" content=\"fi_FI\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biomark\u00f6rer f\u00f6r Alzheimers sjukdom - Aivobiomarkkeritutkimukset\" \/>\n<meta property=\"og:description\" content=\"Hj\u00e4rnbiomark\u00f6rer M\u00f6jligheterna till v\u00e5rd av Alzheimers sjukdom \u00f6kar hela tiden, och fler och fler unders\u00f6kningar tyder p\u00e5 att man uppn\u00e5r den st\u00f6rsta och mest l\u00e5ngvariga nyttan n\u00e4r v\u00e5rden kan p\u00e5b\u00f6rjas s\u00e5 tidigt som m\u00f6jligt. En tidig diagnostik av sjukdomen \u00e4r utmanande. En diagnostisering som grundar sig p\u00e5 en klinisk symptombild f\u00f6ruts\u00e4tter oftast en tillr\u00e4ckligt l\u00e5ngvarig [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/?lang=sv\" \/>\n<meta property=\"og:site_name\" content=\"Aivobiomarkkeritutkimukset\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-02T07:40:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/wp-content\/uploads\/sites\/112\/2020\/11\/ADBIOMARKKERI-Logo-right-600-levea.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"184\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Arvioitu lukuaika\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minuuttia\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/sites.uef.fi\\\/aivobiomarkkeritutkimukset\\\/?lang=sv\",\"url\":\"https:\\\/\\\/sites.uef.fi\\\/aivobiomarkkeritutkimukset\\\/?lang=sv\",\"name\":\"Biomark\u00f6rer f\u00f6r Alzheimers sjukdom - Aivobiomarkkeritutkimukset\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sites.uef.fi\\\/aivobiomarkkeritutkimukset\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/sites.uef.fi\\\/aivobiomarkkeritutkimukset\\\/?lang=sv#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/sites.uef.fi\\\/aivobiomarkkeritutkimukset\\\/?lang=sv#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sites.uef.fi\\\/alzheimermarkkeritutkimukset\\\/wp-content\\\/uploads\\\/sites\\\/112\\\/2020\\\/11\\\/ADBIOMARKKERI-Logo-right-600-levea-300x92.jpg\",\"datePublished\":\"2020-06-18T02:42:12+00:00\",\"dateModified\":\"2026-04-02T07:40:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/sites.uef.fi\\\/aivobiomarkkeritutkimukset\\\/?lang=sv#breadcrumb\"},\"inLanguage\":\"fi\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/sites.uef.fi\\\/aivobiomarkkeritutkimukset\\\/?lang=sv\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fi\",\"@id\":\"https:\\\/\\\/sites.uef.fi\\\/aivobiomarkkeritutkimukset\\\/?lang=sv#primaryimage\",\"url\":\"https:\\\/\\\/sites.uef.fi\\\/alzheimermarkkeritutkimukset\\\/wp-content\\\/uploads\\\/sites\\\/112\\\/2020\\\/11\\\/ADBIOMARKKERI-Logo-right-600-levea-300x92.jpg\",\"contentUrl\":\"https:\\\/\\\/sites.uef.fi\\\/alzheimermarkkeritutkimukset\\\/wp-content\\\/uploads\\\/sites\\\/112\\\/2020\\\/11\\\/ADBIOMARKKERI-Logo-right-600-levea-300x92.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/sites.uef.fi\\\/aivobiomarkkeritutkimukset\\\/?lang=sv#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/sites.uef.fi\\\/aivobiomarkkeritutkimukset\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biomark\u00f6rer f\u00f6r Alzheimers sjukdom\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/sites.uef.fi\\\/aivobiomarkkeritutkimukset\\\/#website\",\"url\":\"https:\\\/\\\/sites.uef.fi\\\/aivobiomarkkeritutkimukset\\\/\",\"name\":\"Aivobiomarkkeritutkimukset\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/sites.uef.fi\\\/aivobiomarkkeritutkimukset\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fi\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biomark\u00f6rer f\u00f6r Alzheimers sjukdom - Aivobiomarkkeritutkimukset","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/?lang=sv","og_locale":"fi_FI","og_type":"article","og_title":"Biomark\u00f6rer f\u00f6r Alzheimers sjukdom - Aivobiomarkkeritutkimukset","og_description":"Hj\u00e4rnbiomark\u00f6rer M\u00f6jligheterna till v\u00e5rd av Alzheimers sjukdom \u00f6kar hela tiden, och fler och fler unders\u00f6kningar tyder p\u00e5 att man uppn\u00e5r den st\u00f6rsta och mest l\u00e5ngvariga nyttan n\u00e4r v\u00e5rden kan p\u00e5b\u00f6rjas s\u00e5 tidigt som m\u00f6jligt. En tidig diagnostik av sjukdomen \u00e4r utmanande. En diagnostisering som grundar sig p\u00e5 en klinisk symptombild f\u00f6ruts\u00e4tter oftast en tillr\u00e4ckligt l\u00e5ngvarig [&hellip;]","og_url":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/?lang=sv","og_site_name":"Aivobiomarkkeritutkimukset","article_modified_time":"2026-04-02T07:40:13+00:00","og_image":[{"width":600,"height":184,"url":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/wp-content\/uploads\/sites\/112\/2020\/11\/ADBIOMARKKERI-Logo-right-600-levea.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Arvioitu lukuaika":"4 minuuttia"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/?lang=sv","url":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/?lang=sv","name":"Biomark\u00f6rer f\u00f6r Alzheimers sjukdom - Aivobiomarkkeritutkimukset","isPartOf":{"@id":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/?lang=sv#primaryimage"},"image":{"@id":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/?lang=sv#primaryimage"},"thumbnailUrl":"https:\/\/sites.uef.fi\/alzheimermarkkeritutkimukset\/wp-content\/uploads\/sites\/112\/2020\/11\/ADBIOMARKKERI-Logo-right-600-levea-300x92.jpg","datePublished":"2020-06-18T02:42:12+00:00","dateModified":"2026-04-02T07:40:13+00:00","breadcrumb":{"@id":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/?lang=sv#breadcrumb"},"inLanguage":"fi","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/?lang=sv"]}]},{"@type":"ImageObject","inLanguage":"fi","@id":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/?lang=sv#primaryimage","url":"https:\/\/sites.uef.fi\/alzheimermarkkeritutkimukset\/wp-content\/uploads\/sites\/112\/2020\/11\/ADBIOMARKKERI-Logo-right-600-levea-300x92.jpg","contentUrl":"https:\/\/sites.uef.fi\/alzheimermarkkeritutkimukset\/wp-content\/uploads\/sites\/112\/2020\/11\/ADBIOMARKKERI-Logo-right-600-levea-300x92.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/?lang=sv#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/"},{"@type":"ListItem","position":2,"name":"Biomark\u00f6rer f\u00f6r Alzheimers sjukdom"}]},{"@type":"WebSite","@id":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/#website","url":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/","name":"Aivobiomarkkeritutkimukset","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fi"}]}},"_links":{"self":[{"href":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/wp-json\/wp\/v2\/pages\/49","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/wp-json\/wp\/v2\/comments?post=49"}],"version-history":[{"count":2,"href":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/wp-json\/wp\/v2\/pages\/49\/revisions"}],"predecessor-version":[{"id":3267,"href":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/wp-json\/wp\/v2\/pages\/49\/revisions\/3267"}],"wp:attachment":[{"href":"https:\/\/sites.uef.fi\/aivobiomarkkeritutkimukset\/wp-json\/wp\/v2\/media?parent=49"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}